
Opinion|Videos|August 19, 2024
Dr Albiges Reviews Long term follow up data from KEYNOTE-B61
Author(s)Laurence Albiges, MD, PhD
Laurence Albiges, MD, PhD, analyzes the long-term follow-up data from the phase 2 KEYNOTE-B61 study, highlighting the observed overall survival (OS) rate associated with adjuvant pembrolizumab.
Advertisement
Episodes in this series

- Please discuss long term follow up data from the phase 2 KEYNOTE-B61 study investigatingpembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell RCC.
- Please provide a brief background surrounding KEYNOTE-B61
- How did the response rates compare across histologies?
- Considering the observed OS benefit with adjuvant pembro, do you intend to approach its adjuvant use in a similar or different manner in this treatment setting?
Advertisement
Related to this article

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The Pan-Mass Challenge donated a record $80 million to Dana-Farber Cancer Institute to support cancer research, treatment, and patient care.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5


